Icure Pharmaceutical Incorporation (KOSDAQ:175250)
1,920.00
-57.00 (-2.88%)
At close: May 12, 2025, 3:30 PM KST
KOSDAQ:175250 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 1,049 | -31,420 | -41,766 | -38,167 | -12,614 | Upgrade
|
Depreciation & Amortization | 8,786 | 9,043 | 8,216 | 7,778 | 7,024 | Upgrade
|
Loss (Gain) From Sale of Assets | -31,657 | -51.52 | 70.11 | -490.69 | 42.01 | Upgrade
|
Asset Writedown & Restructuring Costs | 8,791 | - | 1,292 | 3,040 | 18.29 | Upgrade
|
Loss (Gain) From Sale of Investments | 1,875 | 552.81 | 2,027 | 159.8 | -926.63 | Upgrade
|
Loss (Gain) on Equity Investments | -417.96 | -1,213 | 2,259 | 3,228 | -6,067 | Upgrade
|
Stock-Based Compensation | -11.64 | 81.65 | 296.37 | 575.49 | 200.49 | Upgrade
|
Provision & Write-off of Bad Debts | 861.85 | 881.12 | 1,088 | 1,742 | 907.07 | Upgrade
|
Other Operating Activities | 2,099 | 7,822 | 9,779 | 3,046 | 4,766 | Upgrade
|
Change in Accounts Receivable | -3,877 | -418.55 | 658.13 | 6,273 | -4,103 | Upgrade
|
Change in Inventory | -170.24 | -2,473 | 6,431 | -4,888 | -2,998 | Upgrade
|
Change in Accounts Payable | -607.83 | 1,831 | 146.21 | -6,911 | 2,383 | Upgrade
|
Change in Other Net Operating Assets | -3,774 | 1,847 | -1,780 | -1,615 | -1,036 | Upgrade
|
Operating Cash Flow | -17,054 | -13,519 | -11,282 | -26,228 | -12,403 | Upgrade
|
Capital Expenditures | -2,023 | -2,225 | -4,197 | -5,701 | -22,996 | Upgrade
|
Sale of Property, Plant & Equipment | 68,028 | 284.52 | 187.72 | 1,782 | 33.26 | Upgrade
|
Cash Acquisitions | -246.43 | - | -46.71 | - | -224 | Upgrade
|
Divestitures | - | 2.5 | - | 0.47 | - | Upgrade
|
Sale (Purchase) of Intangibles | -486.8 | -401.25 | -1,767 | -1,006 | -4,268 | Upgrade
|
Investment in Securities | -3,254 | 2,931 | 11,739 | -13,186 | 34,275 | Upgrade
|
Other Investing Activities | 1,290 | -294.53 | -351.52 | 159.86 | 2,305 | Upgrade
|
Investing Cash Flow | 61,985 | 3,047 | 2,232 | -20,318 | 6,034 | Upgrade
|
Short-Term Debt Issued | 3,700 | 6,610 | 5,000 | 2,000 | 5,700 | Upgrade
|
Long-Term Debt Issued | 19,849 | 14,842 | 4,000 | 53,773 | 8,000 | Upgrade
|
Total Debt Issued | 23,549 | 21,452 | 9,000 | 55,773 | 13,700 | Upgrade
|
Short-Term Debt Repaid | -34,410 | -500 | -417.63 | - | -2,700 | Upgrade
|
Long-Term Debt Repaid | -23,388 | -54,689 | -448.05 | -2,382 | -7,460 | Upgrade
|
Total Debt Repaid | -57,798 | -55,189 | -865.68 | -2,382 | -10,160 | Upgrade
|
Net Debt Issued (Repaid) | -34,249 | -33,738 | 8,134 | 53,391 | 3,540 | Upgrade
|
Issuance of Common Stock | - | - | 33,724 | - | - | Upgrade
|
Repurchase of Common Stock | - | - | -547.51 | - | - | Upgrade
|
Other Financing Activities | 170.68 | -26.13 | 3 | 1,957 | 754.55 | Upgrade
|
Financing Cash Flow | -34,078 | -33,764 | 41,813 | 58,398 | 4,295 | Upgrade
|
Foreign Exchange Rate Adjustments | 0 | -1.67 | 0 | 41.97 | -0.22 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | -0 | - | -0 | - | Upgrade
|
Net Cash Flow | 10,853 | -44,237 | 32,763 | 11,893 | -2,075 | Upgrade
|
Free Cash Flow | -19,077 | -15,744 | -15,479 | -31,929 | -35,399 | Upgrade
|
Free Cash Flow Margin | -27.57% | -27.72% | -26.07% | -49.67% | -39.27% | Upgrade
|
Free Cash Flow Per Share | -507.93 | -419.20 | -664.50 | -1474.52 | -1793.49 | Upgrade
|
Cash Interest Paid | 3,492 | 3,619 | 1,517 | 1,177 | 1,097 | Upgrade
|
Cash Income Tax Paid | -134.21 | -92.53 | 176.13 | 298.18 | 356.09 | Upgrade
|
Levered Free Cash Flow | -8,793 | -18,632 | 8,609 | -28,205 | -36,644 | Upgrade
|
Unlevered Free Cash Flow | -5,600 | -15,076 | 13,158 | -24,817 | -34,728 | Upgrade
|
Change in Net Working Capital | 619.64 | 4,246 | -27,540 | 7,639 | 4,981 | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.